A clinical trial developed by a Taiwanese research team has offered a glimmer of hope for patients of neuroblastoma, a malignant cancer that appears in early childhood, a press statement released by the Academia Sinica said.
The research team at the research institute has proven that a combination of anti-cancer monoclonal antibodies (mAbs) with cytokines (natural hormones that help the immune system) is an effective anti-cancer therapy.
The new immunotherapy treatment pioneered by the research team, headed by Alice Yu (陳鈴津), deputy director of Academia Sinica’s Genomics Research Center, is the first study that confirms that immunotherapy is effective in improving cure rates for this childhood cancer, the statement said.
Yu, a pediatrician, has been working on the therapy for more than 20 years. She completed the Phase I and Phase II trials of this antibody at the University of California in San Diego.
The latest Phase III trial was sponsored by the US-based Children’s Oncology Group (COG), a cancer research organization, and the National Cancer Institute of the National Institutes of Health in the US. The latest results included children with neuroblastoma from many parts of the world.
Neuroblastoma is a malignant cancer occurring in early childhood in which the cancer cells arise from the nerve cells in the neck, chest or abdomen.
It is the most common cancer diagnosed in the first year of life and is responsible for 15 percent of cancer-related deaths in children.
The Phase III study showed that children with high risk neuroblastoma who received the new antibody-based immunotherapy (chimeric anti-GD2 antibody ch14.18) have a 20 percent better chance of living free of cancer, a significantly improved cure rate.
So far, Yu said, all US Federal Drug Administration (FDA) approved therapeutic anti-cancer mAbs or vaccines are directed against protein or glycoprotein antigens.
“The Phase III clinical trial is the first mAb targeting a glycolipid that has been shown to be effective,” Yu said.
More importantly, she added, this is the first study that proves that immunotherapy is effective in improving cure rates for this childhood cancer and her team is now focusing on making sure immunotherapy can be available to all children with this disease and on improving results.
COG Chairman Gregory Reaman stated in a press release that the clinical benefit of this approach against the notoriously stubborn child cancer is extraordinary and that the COG is anxious to continue its investigation to better define the toxicities and confirm its satisfactory risk-benefit ratio.
“We are hopeful that that this further study will result in commercialization and FDA approval and licensing of this experimental immunotherapeutic agent so that it can be made readily available as standard therapy to all children with this dreaded disease,” Reaman said in the statement.
Conventional treatment for the disease includes surgery, intensive chemotherapy with stem cell rescue (in which patients’ stem cells removed before treatment are returned after chemotherapy to repopulate the blood and immune system) and radiation therapy.
Despite these aggressive measures, only 30 percent of patients survive.
The immunotherapy evaluated in this study targets a specific glycolipid (sugar and fat) molecule on neuroblastoma cells called GD2 — which inhibits the immune system from attacking cancer cells — with an antibody called ch14.18.
This antibody binds to GD2 and provokes an attack by different types of immune cells against the cancer.
In her study, Yu and her colleagues compared the two-year event-free survival rate (the ratio of patients who were still alive and did not experience a recurrence) of 113 neuroblastoma patients who received the standard treatment (retinoic acid) plus the newly developed immunotherapy with 113 similar patients who only received the standard treatment.
The event-free survival rate for the immunotherapy group was 66 percent, compared to 46 percent for the standard treatment group. The most common side effects in the immunotherapy group were pain, vascular leak syndrome and allergic reactions.
As the study is the first effective immunotherapy reported for the disease and the first improvement on neuroblastoma cure rates of the last 10 years, it has drawn worldwide attention and was reported in USA Today and by US television network CBS.
It is estimated that it will take at least another two years to get FDA approval for the therapy.
Upon its completion next year, the new Tamkang Bridge (淡江大橋) in New Taipei City is to be an important landmark in Taiwan, alongside Taipei 101, Minister of Transportation and Communications Chen Shi-kai (陳世凱) said today. The bridge is scheduled to be completed in December next year and open to the public in the first half of 2026, connecting New Taipei City’s Tamsui (淡水) and Bali (八里) districts. It is an asymmetric single-tower suspension bridge, nearly 70 stories tall, designed by world-famous architect Zaha Hadid. The bridge aims to alleviate traffic in Tamsui and on the Guandu Bridge (關渡大橋), in addition to increasing the
EXERCISES: A 2022 article by a Chinese intelligence expert identified at least six People’s Liberation Army assault boats hidden inside the Hong Kong-flagged ship A Hong Kong-flagged cargo ship that had been docked at Taichung Port and which previously took part in Chinese military exercises departed from the port on Saturday, the Taiwan International Ports Corp’s Taichung branch said yesterday. The statement came in response to a post on the social media platform X by Taiwan-based journalist Chris Horton that said the ship, the SCSC Fortune, had been docked at the port since Tuesday and questioned whether Taiwan has any rules regarding foreign civilian vessels that have participated in People’s Liberation Army (PLA) exercises. Horton referenced a 2022 article by Chinese intelligence expert Rod Lee that
PROBLEMATIC: Popular hotpot restaurant chains were among the list of restaurants that failed the inspection and have been ordered to remove bad ingredients The Taipei Department of Health’s latest inspection of hotpot ingredients in hotpot restaurants resulted in a 16.7 percent failure rate. Eight vegetables had excessive pesticide residue and two other items had aflatoxin and excessive preservatives. As the weather is getting colder, more people eat at hotpot restaurants so a random inspection of ingredients was conducted in October to ensure food safety, the department said. Food and Drug Division Director Lin Kuan-chen (林冠蓁) said 60 different ingredients were tested: 15 high-risk vegetables, 15 processed food items, 10 soy-based food items, five meat items, five lamb items, five seafood items and five peanut powder
PUBLIC TRANSPORT: As some roads would be fully or partially closed, people are advised to take the MRT, with services expanded to accommodate more riders This year’s Taipei Marathon, which has obtained its first gold label certification from World Athletics, is to be held from 5am to 1pm tomorrow and would have 28,000 participants. The race is to start from the Taipei City Plaza and would go through major roads throughout the city, with traffic control implemented from 6am to 2pm, officials said. The Taipei Mass Rapid Transit (MRT) system and New Taipei City MRT Circle line would start operating at 5am on the day of the race, they said. The race would cover Renai Road, Xinyi Road, Hangzhou S Road, Aiguo east and west roads,
RSS